Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:506112C25.9
Who is this for?
Show terms as
1FDA treatments1Active trials6Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mixed neuroendocrine and non-neuroendocrine neoplasm of the pancreas, often called MiNEN (pronounced 'my-nen'), is a rare type of pancreatic cancer. It is also sometimes called mixed adenoneuroendocrine carcinoma, or MANEC. What makes this tumor unusual is that it contains two very different types of cancer cells growing together in the same tumor. One part behaves like a neuroendocrine tumor — a cancer that starts in hormone-producing cells. The other part behaves like a more common type of pancreatic cancer, such as an adenocarcinoma, which starts in gland-forming cells. By definition, each component makes up at least 30% of the tumor. The pancreas is a gland in your abdomen that helps with digestion and controls blood sugar. When a MiNEN develops there, it can disrupt both of these functions. Because the tumor has two different cell types, it can be harder to diagnose and treat than a single-type pancreatic cancer. Symptoms often include abdominal pain, unexplained weight loss, jaundice (yellowing of the skin and eyes), nausea, and changes in blood sugar. Treatment usually involves surgery when possible, combined with chemotherapy. Because this cancer is so rare, treatment decisions are often made by a team of specialists at a major cancer center. The prognosis depends heavily on how advanced the cancer is at diagnosis and which component of the tumor is more aggressive.

Also known as:

Key symptoms:

Abdominal or upper belly painUnexplained weight lossYellowing of the skin or eyes (jaundice)Nausea and vomitingLoss of appetiteNew or worsening diabetes or blood sugar problemsPale or greasy stoolsDark urineFatigue and weaknessA lump or mass felt in the abdomenBack painBloating or feeling full quickly

Inheritance

Sporadic

Usually appears on its own, not inherited from a parent

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

3 events
Mar 2026INREBIC: New indication approved
FDAcompleted
Oct 2024EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms

European Institute of Oncology

TrialRECRUITING
Nov 1988

Metrogel: FDA approved

Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas

FDAcompleted

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

1 available

Metrogel

Metronidazole (topical)· Galderma Laboratories, Inc.Orphan Drug

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
EpigenOMic Determinants of the Neuroendocrine Phenotype As Biomarkers for Neuroendocrine Neoplasms
Actively Recruiting
PI: Nicola Fazio, MD (European Institute of Oncology) · Sites: Milan · Age: 1899 yrs

Specialists

6 foundView all specialists →
SP
Sandip P Patel
Birmingham, Alabama
Specialist

Rare Disease Specialist

PI on 1 active trial
SW
Sarah B Whittle
Specialist
PI on 1 active trial3 Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas publications
SM
Scot C. Remick, MD
SCARBOROUGH, ME
Specialist
PI on 9 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreasForum →

No community posts yet. Be the first to share your experience with Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas.

Start the conversation →

Latest news about Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas

1 articles
NewsFDA
FDA Approves INREBIC
INREBIC (FEDRATINIB HYDROCHLORIDE) received FDA approval.
See all news about Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What stage is my cancer, and has it spread beyond the pancreas?,Which part of my tumor — the neuroendocrine or the other type — is more aggressive, and how does that affect my treatment?,Am I a candidate for surgery, and what would that involve?,What chemotherapy regimen do you recommend, and why?,Should my tumor be tested for specific genetic mutations that might guide treatment?,Are there any clinical trials I might be eligible for?,What support services — such as nutrition counseling, pain management, or mental health support — are available to me?

Common questions about Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas

What is Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?

Mixed neuroendocrine and non-neuroendocrine neoplasm of the pancreas, often called MiNEN (pronounced 'my-nen'), is a rare type of pancreatic cancer. It is also sometimes called mixed adenoneuroendocrine carcinoma, or MANEC. What makes this tumor unusual is that it contains two very different types of cancer cells growing together in the same tumor. One part behaves like a neuroendocrine tumor — a cancer that starts in hormone-producing cells. The other part behaves like a more common type of pancreatic cancer, such as an adenocarcinoma, which starts in gland-forming cells. By definition, each

How is Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas inherited?

Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas typically begin?

Typical onset of Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?

Yes — 1 recruiting clinical trial is currently listed for Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas?

6 specialists and care centers treating Mixed neuroendocrine and non-neuroendocrine neoplasm of pancreas are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.